BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
- Conditions
- Multiple Myeloma
- Interventions
- Biological: BMS-901608 (Elotuzumab) 20 mgBiological: BMS-901608 (Elotuzumab) 10 mg
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT01241292
- Locations
- 🇯🇵
Local Institution, Niigata-shi, Niigata, Japan
Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 104
- Registration Number
- NCT01240980
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
🇺🇸Comprehensive Phase One, Miramar, Florida, United States
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
- Conditions
- LymphomaMultiple Myeloma
- Interventions
- Biological: Elotuzumab (BMS-901608; HuLuc63)
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 646
- Registration Number
- NCT01239797
- Locations
- 🇺🇸
Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Ut Southwestern Medical Center, Dallas, Texas, United States
Multiple Ascending Dose of BMS-911543
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 98
- Registration Number
- NCT01236352
- Locations
- 🇺🇸
The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇦🇺Local Institution, Melbourne, Victoria, Australia
🇺🇸The Mount Sinai School Of Medicine, New York, New York, United States
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
- Conditions
- HIV
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 525
- Registration Number
- NCT01236235
- Locations
- 🇪🇸
Local Institution, Zaragoza, Spain
Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection
- Conditions
- HIV
- Interventions
- Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT01232127
- Locations
- 🇬🇧
Local Institution, London, Greater London, United Kingdom
Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
- Conditions
- Irritability Associated With Autistic Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 215
- Registration Number
- NCT01227668
- Locations
- 🇺🇸
Childrens Specialty Gr., Pllc, Norfolk, Virginia, United States
🇺🇸Stony Brook University School Of Medicine, Stony Brook, New York, United States
🇺🇸Children'S Specialized Hosp, Toms River, New Jersey, United States
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 77
- Registration Number
- NCT01225172
- Locations
- 🇺🇸
Oncology Care Associates, P.A., Wheaton, Maryland, United States
🇺🇸Presbyterian Hospital Cancer Research, Charlotte, North Carolina, United States
🇺🇸University Of Virginia Health System, Charlottesville, Virginia, United States
Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept
- First Posted Date
- 2010-10-15
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT01221636
- Locations
- 🇺🇸
Local Institution, Austin, Texas, United States
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT01218477
- Locations
- 🇺🇸
University Of California Medical Center, San Francisco, California, United States
🇺🇸Ut M.D. Anderson Cancer Center, Houston, Texas, United States
🇬🇧Local Institution, Glasgow, United Kingdom